In mid-2007, OSI's revenues were based primarily on proceeds from Tarceva sales (which are shared with Genentech and Hoffmann–La Roche) and royalty payments related to dipeptidyl-peptidase IV inhibitor intellectual property.
Pada pertengahan 2007, pendapatan OSI didasarkan terutama pada hasil penjualan Tarceva (yang berbagi dengan Genentech serta Hoffmann-La Roche) dan pembayaran royalti yang berkaitan dengan kekayaan intelektual dari inhibitor dipeptidil-peptidase IV.